Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 291mg equivalent to 250 mg ceftazidime;   - powder for injection - 250 mg - active: ceftazidime pentahydrate 291mg equivalent to 250 mg ceftazidime   excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 2.328 g equivalent to 2g ceftazidime;  ;   - powder for injection - 2 g - active: ceftazidime pentahydrate 2.328 g equivalent to 2g ceftazidime     excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 582mg equivalent to 500 mg ceftazidime;  ;   - powder for injection - 500 mg - active: ceftazidime pentahydrate 582mg equivalent to 500 mg ceftazidime     excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - ceftazidime pentahydrate 1 g - powder for injection - 1 g - active: ceftazidime pentahydrate 1 g excipient: sodium carbonate - treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - ceftazidime pentahydrate 2 g - powder for injection - 2 g - active: ceftazidime pentahydrate 2 g excipient: sodium carbonate - treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - ceftazidime pentahydrate 500mg - powder for injection - 500 mg - active: ceftazidime pentahydrate 500mg excipient: sodium carbonate - treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - ceftazidime pentahydrate 1.1648 g equivalent to ceftazidime 1 g (sterile);   - powder for injection - 1 g - active: ceftazidime pentahydrate 1.1648 g equivalent to ceftazidime 1 g (sterile)   excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1 pharmacodynamic properties). indications include: - severe infections e.g. - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - ceftazidime pentahydrate 2.3296 g equivalent to ceftazidime 2 g (sterile);   - powder for injection - 2 g - active: ceftazidime pentahydrate 2.3296 g equivalent to ceftazidime 2 g (sterile)   excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1 pharmacodynamic properties). indications include: - severe infections e.g. - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - ceftazidime pentahydrate 1.16 g equivalent to ceftazidime 1g - powder for injection - 1 g - active: ceftazidime pentahydrate 1.16 g equivalent to ceftazidime 1g excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: - severe infections: for example: · septicaemia, bacteraemia, peritonitis, meningitis. · infections in immunosuppressed patients. · infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - ceftazidime pentahydrate 2.33 g equivalent to ceftazidime 2g - powder for injection - 2 g - active: ceftazidime pentahydrate 2.33 g equivalent to ceftazidime 2g excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: - severe infections: for example: · septicaemia, bacteraemia, peritonitis, meningitis. · infections in immunosuppressed patients. · infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)